Physician profile
Young Kwak
NPI 1407182249
$8,772.60
in general payments reported to CMS, 2019-2025
49 companies · $2,518 in 2025
The $2,518 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,340 · 2020: $293 · 2021: $109 · 2022: $854 · 2023: $1,781 · 2024: $1,878 · 2025: $2,518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,176.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $989.54 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $790.92 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $741.57 | 2019-2025 | Jardiance, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $699.40 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $646.09 | 2019-2025 | |
| Abbott Laboratories | $534.16 | 2021-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $497.97 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $404.87 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $311.62 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $304.13 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $292.58 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| E.R. Squibb & Sons, L.L.C. | $256.73 | 2022-2025 | Eliquis |
| Amgen INC. | $254.50 | 2019-2025 | Evenity, Prolia, Repatha |
| Exact Sciences Corporation | $226.49 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $188.75 | 2019-2024 | Veozah |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Young Kwak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.